<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243838</url>
  </required_header>
  <id_info>
    <org_study_id>20170328</org_study_id>
    <nct_id>NCT03243838</nct_id>
  </id_info>
  <brief_title>Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer</brief_title>
  <acronym>LANCET</acronym>
  <official_title>A Open-label, Prospective, Phase 1b Trial of Neoadjuvant Chemotherapy Combined With Small Dose of Apatinib in the Treatment of Early Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple-negative breast cancer (TNBC) is a special type of breast cancer, endocrine therapy&#xD;
      and targeted therapy are completely ineffective, chemotherapy is currently the only effective&#xD;
      treatment. How to improve postoperative pathologic complete response（pCR）of neoadjuvant&#xD;
      chemotherapy is critical problem to prolong overall survival (OS) of TNBC patients. Apatinib&#xD;
      is a new oral small molecule tyrosine protease inhibitor, it is effective in inhibiting&#xD;
      angiogenesis with a very low concentration. So the standard neoadjuvant chemotherapy regimen&#xD;
      of docetaxel and carboplatin combined with apatinib may improve the postoperative PCR and OS&#xD;
      of TNBC patients. Safety and tolerability assessed by number of grade 3 and 4 toxicities and&#xD;
      hospitalizations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">April 2, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>one year</time_frame>
    <description>pathologic complete response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>twenty years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>docetaxel/carboplatin combined with apatinib as Neoadjuvant Treatment for Triple-Negative Breast Cancer</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically or cytologically confirmed Triple-Negative invasive breast carcinoma&#xD;
&#xD;
          -  Clinical stageIIA-IIIB&#xD;
&#xD;
          -  Patients must have measurable disease as defined by palpable lesion with caliper&#xD;
             and/or a positive mammogram or ultrasound. Bilateral mammogram and clip placement is&#xD;
             required for study entry. Baseline measurements of the indicator lesions must be&#xD;
             recorded on the Patient Registration Form. To be valid for baseline, the measurements&#xD;
             must have been made within the 14 days if palpable. If not palpable, a mammogram or&#xD;
             MRI must be done within 14 days. If palpable, a mammogram or MRI must be done within 2&#xD;
             months prior to study entry. If clinically indicated, x-rays and scans must be done&#xD;
             within 28 days of study entry.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of&#xD;
             study entry&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Adequate organ function within 2 weeks of study entry: Absolute neutrophil count&#xD;
             &gt;1500/mm3, Hgb &gt;9.0 g/dl and platelet count &gt;100,000/mm3 Total bilirubin &lt; upper limit&#xD;
             of normal Creatinine &lt; 1.5 mg/dL or calculated cranial cruciate ligament (CrCL)&#xD;
             &gt;50mL/min using the Cockcroft Gault equation serum glutamate oxaloacetate&#xD;
             transaminase(SGOT)(AST) or serum glutamic oxaloacetic transaminase(SGPT)(ALT) and&#xD;
             Alkaline Phosphatase must be within the range allowing for eligibility&#xD;
&#xD;
          -  Patients must be over 18 years old&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of treatment&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (barrier method of birth control) prior to study entry and for the duration of study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent,&#xD;
             targeted therapy or radiation therapy for current breast cancer. Patients with history&#xD;
             of breast cancer greater than 5 years from initial diagnosis are eligible for the&#xD;
             study. Patients may not have received anthracycline-based chemotherapy in the past.&#xD;
             Patients with history of ductal carcinoma in situ(DCIS) are eligible if there were&#xD;
             treated with surgery alone.&#xD;
&#xD;
          -  History of previous or current malignancy at other sites with the exception of&#xD;
             adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma&#xD;
             of the skin. Patients with a history of other malignancies, who remain disease free&#xD;
             for greater than five years are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kun Wang</last_name>
    <phone>00862083827812</phone>
    <phone_ext>80632</phone_ext>
    <email>gzwangkun@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ciqiu Yang</last_name>
    <phone>00862083827812</phone>
    <phone_ext>80631</phone_ext>
    <email>yangciqiu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong general hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liming Yao</last_name>
      <phone>00862083827812</phone>
      <phone_ext>20984</phone_ext>
      <email>13149395530@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>August 5, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>February 3, 2018</last_update_submitted>
  <last_update_submitted_qc>February 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>KunWang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Triple-Negative Breast Cancer</keyword>
  <keyword>apatinib</keyword>
  <keyword>pCR</keyword>
  <keyword>OS</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

